Thursday May 21, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
Healthcare Fraud Enforcement Just Hit Record Highs. The DOJ Is Just Getting Started — And Device Companies Are Squarely in Frame.
While most of the medtech industry’s attention this spring has been on Marty Makary’s resignation, FDA review backlogs, and the IVL competitive fight, a quieter but arguably more consequential shift has been gathering momentum at the Department of Justice. Last week, MD+DI ran a piece warning that healthcare enforcement will “expand exponentially” under the Trump administration’s restructured enforcement apparatus. For device manufacturers, especially those operating at the kickback-and-billing seam where commercial teams meet physician customers, this is the regulatory story to be tracking.
The numbers tell the story bluntly. False Claims Act recoveries hit a record $6.8 billion in fiscal year 2025 — the highest single-year recovery in the statute’s nearly 40-year history, and more than double the $2.9 billion recovered in FY 2024. Healthcare and life sciences accounted for $5.7 billion of that, or 83 percent. Whistleblowers filed 1,297 qui tam actions, another record. The medical device industry’s specific share was roughly $76 million across five or six enforcement actions — a smaller absolute number than pharma or insurers, but the trajectory is what matters.
The infrastructure is being built quickly, and on purpose
Three things have happened in the past three months that, taken together, indicate this isn’t a one-year spike. On April 1, the DOJ stood up a new National Fraud Enforcement Division, with Colin McDonald sworn in as its first Assistant Attorney General. Acting Attorney General Todd Blanche directed the division on April 7 to take “immediate action” to become a robust litigating arm focused on fraud against taxpayer-funded programs. On April 30, the division announced the West Coast Health Care Fraud Strike Force, spanning Arizona, Nevada, and Northern California — with U.S. Attorneys in those districts specifically calling out medical device and wound care companies as targets, and Silicon Valley described as “ground zero” for technology-enabled healthcare fraud.
The infrastructure underneath is what should genuinely concern compliance officers. The DOJ’s Health Care Fraud Data Fusion Center, launched last June, uses AI and cloud computing to identify billing anomalies at scale — flagging outlier patterns before any human investigator gets involved. As one compliance expert told Medical Economics this spring, “Investigations are increasingly triggered by analytics, so practices get flagged because their data does not look like their peers.” For device manufacturers, the equivalent flags will come from utilization patterns, surgeon-specific implant volumes, and Medicare/Medicaid billing curves that diverge from the field. The first time many companies will hear about an investigation is when the subpoena arrives.
What this looks like on the ground
The clearest recent example of how an enforcement action actually plays out against a device company is the Aesculap Implant Systems settlement, announced last November but worth revisiting because it illustrates the full enforcement model now being scaled. The orthopedic and spine company agreed to pay $38.5 million to resolve allegations that, from 2010 through 2023, it sold its Vega knee replacement system knowing the implants were prone to premature loosening due to bone-cement adhesion problems — causing false Medicare and Medicaid claims for revisions. The settlement also resolved Anti-Kickback Statute allegations that Aesculap paid a Georgia orthopedic surgeon through consulting fees, international travel, and entertainment to induce him to use the device. A separate non-prosecution agreement covered the company’s distribution of two devices — a surgical drill and a sterilization container — without the required FDA clearance, after an employee forged the regulatory documentation.
Three whistleblowers split $4.475 million. The case stitched together the False Claims Act, the Anti-Kickback Statute, and the Food, Drug, and Cosmetic Act in a single coordinated resolution involving DOJ Civil Division, HHS-OIG, FDA’s Office of Criminal Investigations, and the U.S. Attorney’s Office for the Eastern District of Pennsylvania. That convergence — one company, three statutes, four agencies, three relators — is the template the new Strike Force model is built to replicate at higher velocity.
What changes for device companies
A few practical implications worth thinking through. First, the era of “paper” compliance programs is functionally over. Barnes & Thornburg’s annual report flagged that prosecutors are now actively differentiating between compliance programs that exist on a shared drive and ones that operationally function — and that distinction now matters in charging decisions and settlement leverage. Second, private equity-owned device platforms are receiving heightened scrutiny under existing Anti-Kickback and Stark frameworks, particularly where roll-up economics create incentive structures that look like volume inducements. Third, qui tam relators won more healthcare cases without DOJ intervention in FY 2025 than with it — the first time that’s happened — which means even matters DOJ declines can still produce nine-figure recoveries.
The strategic takeaway is straightforward. The FDA-side regulatory burden has been the medtech industry’s dominant compliance focus for a generation. The DOJ-side enforcement burden has now caught up, and it’s arriving with better data infrastructure, more aggressive prosecutorial posture, and a whistleblower pipeline that filed at record volume last year. For device companies whose commercial models touch surgeon relationships, billing intermediaries, or Medicare/Medicaid reimbursement — which is most of them — the next 12 months are a moment to pressure-test compliance programs against the way enforcement is actually being run today, not the way it was five years ago.
SPONSORED BY RŌG HEALTH
Most medical device companies don't fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.